Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.
Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.
NEW YORK, March 25, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
NEW YORK, March 04, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
If you own shares in Eyenovia, Inc. (NASDAQ:EYEN) then it's worth thinking about how it contributes to the volatility...
A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.
Eyenovia, Inc. (NASDAQ:EYEN) shareholders (or potential shareholders) will be happy to see that insider Stuart Grant...
Eyenovia, Inc. (EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, announced that today it closed its previously announced private placement of units which resulted in gross proceeds of $5,984,931 before deducting the placement agent's fees and estimated offering expenses. Each unit consists of (i) one share of common stock, par value $0.0001 per share, (ii) a one-year warrant to purchase 0.5 of a share of common stock, and (iii) a five-year warrant to purchase 0.75 of a share of common stock.
NEW YORK, May 13, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
NEW YORK, NY / ACCESSWIRE / March 25, 2020 / Eyenovia, Inc. (NASDAQ:EYEN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 at 4:30 PM Eastern ...
NEW YORK, March 11, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Applied Materials' (AMAT) technology leadership position and strong product line in Display and Services are likely to reflect on fiscal fourth-quarter results.
NEW YORK, Nov. 13, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has received subscriptions for a private placement in the amount of approximately $6.0 million of units at a price to the public of $2.21425 per unit. Each unit consists of (i) one share of common stock, par value $0.0001 per share, (ii) a one-year warrant to purchase 0.5 of a share of common stock, and (iii) a five-year warrant to purchase 0.75 of a share of common stock. The proceeds of the offering are expected to be used, together with other available funds, for the MicroLine and MicroPine clinical studies, to advance MicroStat’s new drug application, and for working capital and general corporate purposes.
As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).
As of late, it has definitely been a great time to be an investor Eyenovia
NEW YORK, May 06, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that Professor Mark Bullimore, PhD and April Jasper, OD have joined Eyenovia’s Scientific Advisory Board. “We are very pleased to welcome two highly accomplished and respected optometrists to our Scientific Advisory Board,” commented Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer.